194 related articles for article (PubMed ID: 7881637)
1. Immunotherapy of a vaccinia colon oncolysate prepared with interleukin-2 gene-encoded vaccinia virus and interferon-alpha increases the survival of mice bearing syngeneic colon adenocarcinoma.
Tanaka N; Sivanandham M; Wallack MK
J Immunother Emphasis Tumor Immunol; 1994 Nov; 16(4):283-93. PubMed ID: 7881637
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic effect of a vaccinia colon oncolysate prepared with interleukin-2-gene encoded vaccinia virus studied in a syngeneic CC-36 murine colon hepatic metastasis model.
Sivanandham M; Scoggin SD; Tanaka N; Wallack MK
Cancer Immunol Immunother; 1994 Apr; 38(4):259-64. PubMed ID: 8168121
[TBL] [Abstract][Full Text] [Related]
3. A novel dendritic cell-based cancer vaccine produces promising results in a syngenic CC-36 murine colon adenocarcinoma model.
Jack AM; Aydin N; Montenegro G; Alam K; Wallack M
J Surg Res; 2007 May; 139(2):164-9. PubMed ID: 17275030
[TBL] [Abstract][Full Text] [Related]
4. Colon cancer cell vaccine prepared with replication-deficient vaccinia viruses encoding B7.1 and interleukin-2 induce antitumor response in syngeneic mice.
Sivanandham M; Shaw P; Bernik SF; Paoletti E; Wallack MK
Cancer Immunol Immunother; 1998 Jul; 46(5):261-7. PubMed ID: 9690454
[TBL] [Abstract][Full Text] [Related]
5. Vaccinia colon oncolysate immunotherapy for murine hepatic metastases can be modulated with low-dose interleukin-2. Third place winner: Conrad Jobst Award.
Barnavon Y; Iwaki H; Bash JA; Wallack MK
Am Surg; 1988 Dec; 54(12):696-701. PubMed ID: 3264127
[TBL] [Abstract][Full Text] [Related]
6. Active specific immunotherapy with vaccinia colon oncolysate enhances the immunomodulatory and antitumor effects of interleukin-2 and interferon alpha in a murine hepatic metastasis model.
Arroyo PJ; Bash JA; Wallack MK
Cancer Immunol Immunother; 1990; 31(5):305-11. PubMed ID: 2376048
[TBL] [Abstract][Full Text] [Related]
7. Improved immunotherapy of a recombinant carcinoembryonic antigen vaccinia vaccine when given in combination with interleukin-2.
McLaughlin JP; Schlom J; Kantor JA; Greiner JW
Cancer Res; 1996 May; 56(10):2361-7. PubMed ID: 8625312
[TBL] [Abstract][Full Text] [Related]
8. Intratumoral expression of interleukin 23 variants using oncolytic vaccinia virus elicit potent antitumor effects on multiple tumor models via tumor microenvironment modulation.
Chen L; Chen H; Ye J; Ge Y; Wang H; Dai E; Ren J; Liu W; Ma C; Ju S; Guo ZS; Liu Z; Bartlett DL
Theranostics; 2021; 11(14):6668-6681. PubMed ID: 34093846
[No Abstract] [Full Text] [Related]
9. Treatment of murine hepatic metastases with vaccinia colon oncolysates and IL-2.
Barnavon Y; Iwaki H; Bash JA; Brettschneider F; Hilsenbeck S; Darnell E; Wallack MK
J Surg Res; 1988 Dec; 45(6):523-30. PubMed ID: 3263545
[TBL] [Abstract][Full Text] [Related]
10. Vaccine therapy of established tumors in the absence of autoimmunity.
Hodge JW; Grosenbach DW; Aarts WM; Poole DJ; Schlom J
Clin Cancer Res; 2003 May; 9(5):1837-49. PubMed ID: 12738742
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-10 enhances the therapeutic effectiveness of a recombinant poxvirus-based vaccine in an experimental murine tumor model.
Kaufman HL; Rao JB; Irvine KR; Bronte V; Rosenberg SA; Restifo NP
J Immunother; 1999 Nov; 22(6):489-96. PubMed ID: 10570747
[TBL] [Abstract][Full Text] [Related]
12. Active specific immunotherapy of murine colon adenocarcinoma with recombinant vaccinia/interleukin-2-infected tumor cell vaccines.
Bash JA
Ann N Y Acad Sci; 1993 Aug; 690():331-3. PubMed ID: 8368746
[No Abstract] [Full Text] [Related]
13. Vaccinia virus-infected C-C36 colon tumor cell lysates stimulate cellular responses in vitro and protect syngeneic Balb/c mice from tumor cell challenge.
Iwaki H; Barnavon Y; Bash JA; Wallack MK
J Surg Oncol; 1989 Feb; 40(2):90-6. PubMed ID: 2915544
[TBL] [Abstract][Full Text] [Related]
14. Active specific immunotherapy of pulmonary metastasis with vaccinia melanoma oncolysate prepared from granulocyte/macrophage-colony-stimulating-factor-gene-encoded vaccinia virus.
Ju DW; Cao X; Acres B
J Cancer Res Clin Oncol; 1996; 122(12):716-22. PubMed ID: 8954168
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic effect of colon tumor cells expressing FLT-3 ligand plus systemic IL-2 in mice with syngeneic colon cancer.
Sivanandham M; Stavropoulos CI; Kim EM; Mancke B; Wallack MK
Cancer Immunol Immunother; 2002 Apr; 51(2):63-71. PubMed ID: 11904730
[TBL] [Abstract][Full Text] [Related]
16. IL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines: enhancement by simultaneous B7-1 expression.
Rao JB; Chamberlain RS; Bronte V; Carroll MW; Irvine KR; Moss B; Rosenberg SA; Restifo NP
J Immunol; 1996 May; 156(9):3357-65. PubMed ID: 8617961
[TBL] [Abstract][Full Text] [Related]
17. Recombinant vaccinia interleukin-2-infected tumor cell vaccines in immunotherapy of murine colon adenocarcinoma.
Bash JA
J Immunother Emphasis Tumor Immunol; 1993 Nov; 14(4):269-72. PubMed ID: 8280707
[TBL] [Abstract][Full Text] [Related]
18. Complete regression of experimental solid tumors by combination LEC/chTNT-3 immunotherapy and CD25(+) T-cell depletion.
Li J; Hu P; Khawli LA; Epstein AL
Cancer Res; 2003 Dec; 63(23):8384-92. PubMed ID: 14679000
[TBL] [Abstract][Full Text] [Related]
19. Adoptive transfer of anti-CD3-activated CD4+ T cells plus cyclophosphamide and liposome-encapsulated interleukin-2 cure murine MC-38 and 3LL tumors and establish tumor-specific immunity.
Saxton ML; Longo DL; Wetzel HE; Tribble H; Alvord WG; Kwak LW; Leonard AS; Ullmann CD; Curti BD; Ochoa AC
Blood; 1997 Apr; 89(7):2529-36. PubMed ID: 9116299
[TBL] [Abstract][Full Text] [Related]
20. Local delivery of recombinant vaccinia virus expressing secondary lymphoid chemokine (SLC) results in a CD4 T-cell dependent antitumor response.
Flanagan K; Glover RT; Hörig H; Yang W; Kaufman HL
Vaccine; 2004 Jul; 22(21-22):2894-903. PubMed ID: 15246626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
